Session 40 - CROI 2007

Session 40 Oral Abstracts
Clinical Trials, Predictors of Outcome, and Disparities in Care
Wednesday, 10 am - 12 noon
Room: Petree Hall

10:00 am 137	Initial Viral Decay to Assess the Relative Antiretroviral Potency of PI-, NNRTI-, and NRTI-Sparing Regimens for First Line Therapy of HIV-1 Infection: ACTG 5160s (sub-study of A5142) Richard H. Haubrich*¹, S Riddler², H Ribaudo³, G DiRienzo³, K Klingman⁴, K Garren⁵, T George⁶, J Rooney⁷, D Havlir⁸, J Mellors², and the AIDS Clinical Trials Group 5160s Study Team ¹Univ of California, San Diego, US; ²Univ of Pittsburgh, PA, US; ³Harvard Sch of Publ Hlth, Statistical and Data Analysis Ctr, Boston, MA, US; ⁴Div of AIDS, NIAID, NIH, Bethesda, MD, US; ⁵Abbott Labs, Abbott Park, IL, US; ⁶Bristol-Myers Squibb, Plainsboro, NJ, US; ⁷Gilead Sci, Foster City, CA, US; and ⁸Univ of California, San Francisco, US
10:15 am 138	Randomized Comparison in Treatment-naïve Patients of Once-daily vs Twice-daily Lopinavir/ritonavir-based ART and Comparison of Once-daily Self-administered vs Directly Observed Therapy D Mildvan¹, C Tierney², Robert Gross*³, A Andrade⁴, C Lalama², S Eshleman⁴, T Flanigan⁵, J Santana⁶, M Dehlinger⁷, C Flexner⁴, and the ACTG A5073 Study Team ¹Beth Israel Med Ctr, New York, NY, US; ²Harvard Sch of Publ Hlth, Boston, MA, US; ³Univ of Pennsylvania Sch of Med, Philadephia, US; ⁴Johns Hopkins Univ Med Inst, Baltimore, MD, US; ⁵The Miriam Hosp, Providence, RI, US; ⁶Univ of Puerto Rico Sch of Med, San Juan; and ⁷Div of AIDS, NIAID, NIH, Bethesda, MD, US
10:30 am 139	Comparison of Plasma HIV-1 RNA, CD4 Cell Count, and CD38 Expression on CD8 T Cells as Predictors of Progression to AIDS and CD4 Cell Decline among Untreated Participants in the Multicenter AIDS Cohort Study John Mellors*¹, J Margolick², J Phair³, C Rinaldo¹, R Detels⁴, L Jacobson², and A Muñoz² ¹Univ of Pittsburgh, PA, US; ²Johns Hopkins Univ, Baltimore, MD, US; ³Northwestern Univ, Chicago, IL, US; and ⁴Univ of California, Los Angeles, US
10:45 am 140	Predictive Value of Plasma HIV RNA Levels for Rate of CD4 Decline and Clinical Disease Progression Bryan Lau*, S Gange, G Kirk, S Mehta, B Merriman, and R Moore Johns Hopkins Univ, Baltimore, MD, US
11:00 am 141	Carriage of HLA-Bw4 Is Associated with Lower CD4 Cell Counts after Starting HAART: Consistent Findings in the Western Australian HIV Cohort Study and the Swiss HIV Cohort Study Andri Rauch*¹, H Furrer¹, D Nolan², E McKinnon², A Telenti³, and I James² ¹Univ Hosp, Berne, Switzerland; ²CCIBS, Murdoch Univ, Perth, Australia; and ³Univ of Lausanne, Switzerland
11:15 am 142	Disparities in Survival Attributable to Suboptimal HIV Care in the US: Influence of Gender and Race/Ethnicity Elena Losina^1,2, Elena Losina^1,2, B Schackman³, S Sadownik¹, K Gebo⁴, R Walensky^1,5,6, R Walensky^1,5,6, R Walensky^1,5,6, M Weinstein⁷, P Lawrence⁴, W Aaronson¹, R Moore⁴, and D Paltiel⁸ ¹Massachusetts Gen Hosp, Boston, US; ²Boston Univ Sch of Publ Hlth, MA, US; ³Weill Med Coll of Cornell Univ, New York, NY, US; ⁴Johns Hopkins Univ Sch of Med, Baltimore, MD, US; ⁵Harvard Med Sch, Boston, MA, US; ⁶Brigham and Women's Hosp, Boston, MA, US; ⁷Harvard Sch of Publ Hlth, Boston, MA, US; and ⁸Yale Univ Sch of Publ Hlth, New Haven, CT, US
11:30 am 143LB	The HIV Integrase Inhibitor GS-9137 Demonstrates Potent Antiretroviral Activity in Treatment-experienced Patients Andrew R. Zolopa*¹, M Mullen², D Berger³, P Ruane⁴, T Hawkins⁵, L Zhong⁶, S Chuck⁶, J Enejosa⁶, B Kearney⁶, and A Cheng⁶ ¹Stanford Univ, CA, US; ²Mt Sinai Sch of Med, New York, NY, US; ³NorthStar Medical Center, Chicago, IL, USA; ⁴Light Source Med, Los Angeles, CA, US; ⁵Southwest CARE, Santa Fe, NM, US; and ⁶Gilead Sci, Foster City, CA, US
11:45 am 144LB	48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients Anton Pozniak*¹, J Morales-Ramirez², L Mohapi³, M Santoscoy⁴, P Chetchotisakd⁵, M Hereygers⁶, S Vanveggel⁶, M Peeters⁶, B Woodfall⁶, and K Boven⁷ ¹Chelsea and Westminster Hosp, London, UK; ²Clinical Res, San Juan, Puerto Rico; ³Univ of the Witwatersrand, Johannesburg, South Africa; ⁴Hosp Gabriel Mancera IMSS, Mexico City, Mexico; ⁵Srinagarind Hosp, Khon Kaen, Thailand; ⁶Tibotec BVBA, Mechelen, Belgium; and ⁷Tibotec Inc, Yardley, PA, US